ABC-09 (EORTC-1607-GITCG)

An open-label, first line Phase II trial for inoperable, recurrent and metastatic cholangiocarcinoma (intra- and extrahepatic) and gall bladder cancer patients.

This will be a single arm study of first line Pembrolizumab and Gemcitabine/Cisplatin.

All patients on this trial will receive the immunotherapy drug Pembrolizumab in addition to the Gemcitabine/Cisplatin chemotherapy.

ABC-09 is currently open and recruiting at the following UK sites:

University College Hospital, London
Professor John Bridgewater
Medical Oncologist, University College Hospital London
Tel: 020 3447 9093
Fax: 020 3447 9055
Email: j.bridgewater@ucl.ac.uk

Nottingham City Hospital, NG5 1PB
Nottingham University Hospitals NHS Trust

Dr Arvind Arora
Consultant Medical Oncologist
University Hospitals of Nottingham NHS Trust

Tel: 01159 691169 Ext. 72149
Email: arvind.arora@nuh.nhs.uk

For more information on this trial, see: https://clinicaltrials.gov/ct2/show/NCT03260712